{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:21:45Z","timestamp":1778862105836,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:00:00Z","timestamp":1534550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["15-0549"],"award-info":[{"award-number":["15-0549"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00403-018-1853-5","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:19:32Z","timestamp":1534551572000},"page":"607-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata"],"prefix":"10.1007","volume":"310","author":[{"given":"Emma","family":"Guttman-Yassky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Nia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasaman","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erisa","family":"Alia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Taliercio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth N.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,18]]},"reference":[{"issue":"6","key":"1853_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/ijd.12808","volume":"55","author":"MA Atwa","year":"2016","unstructured":"Atwa MA, Youssef N, Bayoumy NM (2016) T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-\u03b1) in patients with alopecia areata: association with clinical type and severity. Int J Dermatol 55(6):666\u2013672","journal-title":"Int J Dermatol"},{"key":"1853_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/1346-8138.12740","volume":"42","author":"S Avitabile","year":"2015","unstructured":"Avitabile S, Sordi D, Garcovich S, Colonna L, De Luca A, Nasorri F et al (2015) Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patients. J Dermatol 42:98\u201399","journal-title":"J Dermatol"},{"issue":"3","key":"1853_CR3","first-page":"e24137","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS (2013) The involvement of the JAK\u2013STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT 2(3):e24137","journal-title":"JAKSTAT"},{"issue":"3","key":"1853_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2014.04.036","volume":"71","author":"K Chiang","year":"2014","unstructured":"Chiang K, Atanaskova Mesinkovska N, Amoretti A, Piliang MP, Kyei A, Bergfeld WF (2014) Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Am Acad Dermatol 71(3):595\u2013597","journal-title":"J Am Acad Dermatol"},{"key":"1853_CR5","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Investig Dermatol 134:2988\u20132990","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1853_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/0974-7753.136748","volume":"6","author":"TR Hollanda de","year":"2014","unstructured":"de Hollanda TR, Sodr\u00e9 CT, Brasil MA, Ramos-E-Silva M (2014) Quality of life in alopecia areata: a case\u2013control study. Int J Trichol 6(1):8\u201312","journal-title":"Int J Trichol"},{"issue":"5","key":"1853_CR7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/all.13128","volume":"72","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Thompson JM, Li WQ, Cho E, Li T, Guttman-Yassky E, Qureshi AA (2017) Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses\u2019 Health Study 2. Allergy 72(5):831\u2013834","journal-title":"Allergy"},{"issue":"8","key":"1853_CR8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/ijd.12994","volume":"55","author":"EH El-Morsy","year":"2016","unstructured":"El-Morsy EH, Eid AA, Ghoneim H, Al-Tameemi KA (2016) Serum level of interleukin-17A in patients with alopecia areata and its relationship to age. Int J Dermatol 55(8):869\u2013874","journal-title":"Int J Dermatol"},{"issue":"2","key":"1853_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00403-016-1617-z","volume":"308","author":"MA Elela","year":"2016","unstructured":"Elela MA, Gawdat HI, Hegazy RA et al (2016) B cell activating factor and T-helper 17 cells: possible synergistic culprits in the pathogenesis of alopecia areata. Arch Dermatol Res 308(2):115\u2013121","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"1853_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jdcr.2017.07.009","volume":"3","author":"A Elkady","year":"2017","unstructured":"Elkady A, Bonomo L, Amir Y, Vekaria AS, Guttman-Yassky E (2017) Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo and alopecia areata. JAAD Case Rep 3(6):477\u2013479","journal-title":"JAAD Case Rep"},{"key":"1853_CR11","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/jid.2011.140","volume":"131","author":"JS Fridman","year":"2011","unstructured":"Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D et al (2011) Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Investig Dermatol 131:1838\u20131844","journal-title":"J Investig Dermatol"},{"issue":"16","key":"1853_CR12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","volume":"366","author":"A Gilhar","year":"2012","unstructured":"Gilhar A, Etzioni A, Paus R (2012) Alopecia areata. N Engl J Med 366(16):1515\u20131525","journal-title":"N Engl J Med"},{"issue":"1","key":"1853_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.autrev.2005.07.001","volume":"5","author":"A Gilhar","year":"2006","unstructured":"Gilhar A, Kalish RS (2006) Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev 5(1):64\u201369","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1853_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-016-0230-4","volume":"18","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Carviel J, Abramovits W (2016) Treating alopecia areata: current practices versus new directions. Am J Clin Dermatol 18(1):67\u201375","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1853_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","volume":"137","author":"E Guttman-Yassky","year":"2016","unstructured":"Guttman-Yassky E, Ungar B, Noda S et al (2016) Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism. J Allergy Clin Immunol 137(1):301\u2013304","journal-title":"J Allergy Clin Immunol"},{"key":"1853_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.chembiol.2011.01.012","volume":"18","author":"C Haan","year":"2011","unstructured":"Haan C, Rolvering C, Raulf F, Kapp M, Druckes P, Thoma G et al (2011) Jak1 has a dominant role over Jak3 in signal transduction through gc-containing cytokine receptors. Chem Biol 18:314\u2013323","journal-title":"Chem Biol"},{"issue":"10","key":"1853_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/1346-8138.12978","volume":"42","author":"YM Han","year":"2015","unstructured":"Han YM, Sheng YY, Xu F et al (2015) Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata. J Dermatol 42(10):981\u2013988","journal-title":"J Dermatol"},{"issue":"2","key":"1853_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N et al (2016) Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 74(2):370\u2013371","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1853_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG (2017) Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 140(3):645\u2013653","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1853_CR20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2013.3049","volume":"149","author":"KP Huang","year":"2013","unstructured":"Huang KP, Mullangi S, Guo Y, Qureshi AA (2013) Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol 149(7):789\u2013794","journal-title":"JAMA Dermatol"},{"key":"1853_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jdermsci.2012.12.003","volume":"69","author":"T Ito","year":"2013","unstructured":"Ito T, Hashizume H, Shimauchi T, Funakoshi A, Ito N, Fukamizu H et al (2013) CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J Dermatol Sci 69:140\u2013147","journal-title":"J Dermatol Sci"},{"issue":"5","key":"1853_CR22","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1172\/JCI28508","volume":"116","author":"Y Iwakura","year":"2006","unstructured":"Iwakura Y, Ishigame H (2006) The IL-23\/IL-17 axis in inflammation. J Clin Investig 116(5):1218\u20131222","journal-title":"J Clin Investig"},{"key":"1853_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ebiom.2016.03.036","volume":"7","author":"A Jabbari","year":"2016","unstructured":"Jabbari A, Cerise JE, Chen JC et al (2016) Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine 7:240\u2013247","journal-title":"EBioMedicine"},{"issue":"4","key":"1853_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"A Jabbari","year":"2015","unstructured":"Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y et al (2015) Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib. EBioMedicine 2(4):351\u2013355","journal-title":"EBioMedicine"},{"key":"1853_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.det.2012.08.014","volume":"31","author":"A Jabbari","year":"2013","unstructured":"Jabbari A, Petukhova L, Cabral RM et al (2013) Genetic basis of alopecia areata. Dermatol Clin 31:109\u2013117","journal-title":"Dermatol Clin"},{"issue":"15","key":"1853_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"M Kennedy Crispin","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG et al (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 1(15):1\u201310","journal-title":"JCI Insight"},{"issue":"1","key":"1853_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5021\/ad.2012.24.1.61","volume":"24","author":"BL Lew","year":"2012","unstructured":"Lew BL, Cho HR, Haw S, Kim HJ, Chung JH, Sim WY (2012) Association between IL17A\/IL17RA gene polymorphisms and susceptibility to alopecia areata in the Korean population. Ann Dermatol 24(1):61\u201365","journal-title":"Ann Dermatol"},{"issue":"4","key":"1853_CR28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1046\/j.1365-2133.2003.05535.x","volume":"149","author":"SP MacDonald Hull","year":"2003","unstructured":"MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG, British Association of Dermatologists (2003) Guidelines for the management of alopecia areata. Br J Dermatol 149(4):692\u2013699","journal-title":"Br J Dermatol"},{"issue":"1764","key":"1853_CR29","first-page":"29","volume":"257","author":"KJ MacLean","year":"2013","unstructured":"MacLean KJ, Tidman MJ (2013) Alopecia areata: more than skin deep. Practitioner 257(1764):29\u201332 (3).","journal-title":"Practitioner"},{"issue":"15","key":"1853_CR30","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N et al (2016) Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight 1(15):e89790","journal-title":"JCI Insight"},{"key":"1853_CR31","doi-asserted-by":"publisher","first-page":"983804","DOI":"10.1155\/2013\/983804","volume":"2013","author":"J Masmoudi","year":"2013","unstructured":"Masmoudi J, Sellami R, Ouali U, Mnif L, Feki I, Amouri M et al (2013) Quality of life in alopecia areata: a sample of tunisian patients. Dermatol Res Pract 2013:983804","journal-title":"Dermatol Res Pract"},{"issue":"5","key":"1853_CR32","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","volume":"166","author":"AG Messenger","year":"2012","unstructured":"Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M (2012) British Association of Dermatologists\u2019 guidelines for the management of alopecia areata 2012. Br J Dermatol 166(5):916\u2013926","journal-title":"Br J Dermatol"},{"issue":"1","key":"1853_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0190-9622(87)70170-4","volume":"17","author":"SS Milgraum","year":"1987","unstructured":"Milgraum SS, Mitchell AJ, Bacon GE, Rasmussen JE (1987) Alopecia areata, endocrine function, and autoantibodies in patients 16 years of age or younger. J Am Acad Dermatol 17(1):57\u201361","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1853_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/jocd.12664","volume":"17","author":"H Morsy","year":"2018","unstructured":"Morsy H, Maher R, Negm D (2018) Correlation between serum IL-17A level and SALT score in patients with alopecia areata before and after NB-UVB therapy. J Cosmet Dermatol 17(3):533\u2013537. \n                    https:\/\/doi.org\/10.1111\/jocd.12664","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"1853_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D et al (2004) Alopecia areata investigational assessment guidelines\u2014Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 51(3):440\u2013447","journal-title":"J Am Acad Dermatol"},{"key":"1853_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1529-8019.2011.01415.x","volume":"24","author":"EA Olsen","year":"2011","unstructured":"Olsen EA (2011) Investigative guidelines for alopecia areata. Dermatol Ther 24:311\u2013319","journal-title":"Dermatol Ther"},{"issue":"1","key":"1853_CR37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/JID.2015.402","volume":"136","author":"L Petukhova","year":"2016","unstructured":"Petukhova L, Christiano AM (2016) Functional interpretation of genome-wide association study evidence in alopecia areata. J Investig Dermatol 136(1):314\u2013317","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1853_CR38","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/jidsymp.2013.5","volume":"16","author":"L Petukhova","year":"2013","unstructured":"Petukhova L, Christiano AM (2013) The genetic architecture of alopecia areata. J Investig Dermatol Symp Proc 16(1):S16\u2013S22","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"7302","key":"1853_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","volume":"466","author":"L Petukhova","year":"2010","unstructured":"Petukhova L et al (2010) Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466(7302):113\u2013117","journal-title":"Nature"},{"key":"1853_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1823-y","author":"Y Ramot","year":"2018","unstructured":"Ramot Y, Marzani B, Pinto D et al (2018) IL-17 inhibition: is it the long-awaited savior for alopecia areata? Arch Dermatol Res. \n                    https:\/\/doi.org\/10.1007\/s00403-018-1823-y","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"1853_CR41","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14712598.2016.1188076","volume":"16","author":"Y Renert-Yuval","year":"2016","unstructured":"Renert-Yuval Y, Guttman-Yassky E (2016) A novel therapeutic paradigm for patients with extensive alopecia areata. Expert Opin Biol Ther 16(8):1005\u20131014","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"1853_CR42","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","volume":"34","author":"Y Renert-Yuval","year":"2017","unstructured":"Renert-Yuval Y, Guttman-Yassky E (2017) The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther 34(7):1594\u20131609","journal-title":"Adv Ther"},{"issue":"7","key":"1853_CR43","doi-asserted-by":"publisher","first-page":"628","DOI":"10.4065\/70.7.628","volume":"70","author":"KH Safavi","year":"1995","unstructured":"Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ (1995) Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70(7):628\u2013633","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1853_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-4362.1992.tb03932.x","volume":"31","author":"WV Shellow","year":"1992","unstructured":"Shellow WV, Edwards JE, Koo JY (1992) Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol 31(3):186\u2013189","journal-title":"Int J Dermatol"},{"issue":"5","key":"1853_CR45","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","volume":"136","author":"M Su\u00e1rez-Fari\u00f1as","year":"2015","unstructured":"Su\u00e1rez-Fari\u00f1as M, Ungar B, Noda S et al (2015) Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing. J Allergy Clin Immunol 136(5):1277\u20131287","journal-title":"J Allergy Clin Immunol"},{"key":"1853_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000350933","volume":"226","author":"A Tanemura","year":"2013","unstructured":"Tanemura A, Oiso N, Nakano M, Itoi S, Kawada A, Katayama I (2013) Alopecia areata: infiltration of Th17 cells in the dermis, particularly around hair follicles. Dermatology 226:333\u2013336","journal-title":"Dermatology"},{"key":"1853_CR47","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/bjd.12396","volume":"169","author":"MK Tembhre","year":"2013","unstructured":"Tembhre MK, Sharma VK (2013) T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol 169:543\u2013548","journal-title":"Br J Dermatol"},{"issue":"9","key":"1853_CR48","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A et al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20(9):1043\u20131049","journal-title":"Nat Med"},{"key":"1853_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00403-015-1539-1","volume":"307","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhao Y, Ye Y, Li S, Qi S, Yang Y et al (2015) Lesional infiltration of mast cells, langerhans cells, T cells and local cytokine profiles in alopecia areata. Arch Dermatol Res 307:319\u2013331","journal-title":"Arch Dermatol Res"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-018-1853-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-018-1853-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-018-1853-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T16:38:10Z","timestamp":1568911090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-018-1853-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,18]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1007\/s00403-018-1853-5","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,18]]},"assertion":[{"value":"2 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"John Nia, Peter Hashim, Yasaman Mansouri, Erisa Alia, Mark Taliercio, and Parth Desai have no conflicts of interest to disclose. Dr. Emma Guttman-Yassky is a board member of Sanofi Aventis, Regeneron, Stiefel\/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Celsus, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae and Leo Pharma; has received consultancy fees from Regeneron, Sanofi, MedImmune, Celgene, Stiefel\/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, LEO Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe and Eli Lilly; and has received research support from Janssen, Regeneron, Celgene, BMS, Novartis, Merck, LEO Pharma and Dermira. Dr. Mark Lebwohl is an employee of Mount Sinai, which receives research funds from Amgen, Anacor Pharmaceuticals Inc, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Janssen Biotech, Kadmon Corporation, LEO Pharmaceuticals, MedImmune, Novartis Pharmaceuticals Corporation, Pfizer, Sun Pharmaceuticals Industries Ltd, and Valeant Pharmaceuticals. The authors did not receive any form of compensation, either directly or indirectly, from any company or agency related to the development, authorship, or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}